Illumina sank -4.3% this afternoon, compared to the S&P 500's day change of 1.0%. Today's losers may turn out to be tomorrow's winners, so be sure to check the stock's fundamentals before making an investment decision:
-
Illumina has logged a -27.1% 52 week change, compared to 22.2% for the S&P 500
-
ILMN has an average analyst rating of buy and is -4.5% away from its mean target price of $143.64 per share
-
Its trailing earnings per share (EPS) is $-7.1, which brings its trailing Price to Earnings (P/E) ratio to -19.3. The Health Care sector's average P/E ratio is 30.21
-
The company's forward earnings per share (EPS) is $2.51 and its forward P/E ratio is 54.7
-
The company has a Price to Book (P/B) ratio of 3.8 in contrast to the Health Care sector's average P/B ratio is 4.08
-
The current ratio is currently 1.7, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
The company's free cash flow for the last fiscal year was $106.0 Million and the average free cash flow growth rate is -34.0%
-
Illumina's revenues have an average growth rate of 5.9% with operating expenses growing at 37.6%. The company's current operating margins stand at -91.2%